Pertuzumab

drugbox
type = mab


source = Human
target = HER2
CAS_number =
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Pertuzumab (also called 2C4, formerly known as Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth. Omnitarg is currently being developed by Genentech.

Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success. [ [http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005]

References

cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043]